<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="159898">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02049294</url>
  </required_header>
  <id_info>
    <org_study_id>RP 14-008</org_study_id>
    <nct_id>NCT02049294</nct_id>
  </id_info>
  <brief_title>Study of the Prednisone Sparing Effect of Xolair (Omalizumab) in Patients With Prednisone-dependent Asthma With Eosinophilic Bronchitis</brief_title>
  <official_title>Randomized Double Blind Placebo Controlled Trial of the Prednisone Sparing Effect of Xolair (Omalizumab) in Patients With Prednisone-dependent Asthma With Eosinophilic Bronchitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Parameswaran Nair</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether addition of Omalizumab enables a
      reduction in the dose of prednisone in patients with asthma and eosinophilic bronchitis.

      This will be a double-blind placebo-controlled, 3-centre, randomized parallel group trial
      divided into two sequential study periods.

      Period 1: After establishing the minimum dose of prednisone to maintain asthma control and
      maintain sputum eosinophils &lt;3%, subjects will be randomized to either placebo or Omalizumab
      for 16 weeks (either once monthly for 4 months or every 2 weeks for 4 months).

      Period 2: standardised prednisone reduction at intervals of 4-weeks until there is a
      clinical and eosinophilic exacerbation or bothersome steroid withdrawal effects.  If
      patients have an exacerbation, they will be treated with prednisone. This patient will
      continue on Omalizumab or placebo during the entire duration of the study but not continue
      the phase of steroid reduction.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>proportion of patients with exacerbations in each study group from week 0 to week 32.</measure>
    <time_frame>Week 0 to Week 32</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>the magnitude of the reduction in the dose of prednisone from week 12 to week 32.</measure>
    <time_frame>week 12 to week 32</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in % sputum eosinophil</measure>
    <time_frame>Week 0 to Week 32</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood eosinophils</measure>
    <time_frame>Week 0 to week 32</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expired Volume in 1 second (FEV1)</measure>
    <time_frame>Week 0 to Week 32</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Forced Expired Volume in 1 second to Forced Vital Capacity (FEV1/VC)</measure>
    <time_frame>Week 0 to Week 32</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Provocative concentration causing a 20% drop in FEV1 (PC20)</measure>
    <time_frame>Week 0 to Week 32</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Control Questionnaire</measure>
    <time_frame>Week 0 to Week 32</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction of exhaled nitric oxide (FeNO)</measure>
    <time_frame>Week 0 to Week 32</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Prednisone Dependent Asthma</condition>
  <condition>Eosinophilic Bronchitis</condition>
  <arm_group>
    <arm_group_label>Omalizumab (Xolair)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dosage/frequency is dependent on body weight (kg) and baseline blood IgE level.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Normal Saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% normal saline equivalent to the dosage/frequency/duration of Omalizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Omalizumab (Xolair)</intervention_name>
    <arm_group_label>Placebo (Normal Saline)</arm_group_label>
    <other_name>Anti IgE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Omalizumab (Xolair)</arm_group_label>
    <other_name>0.9% normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed asthma within the past 2 years (12% bronchodilator reversibility or PC20
             methacholine less than 8 mg/ml)

          -  Sputum eosinophils greater than 3% on at least 2 occasions

          -  Asthma Control Questionnaire (ACQ) &lt;1.5 and sputum eos &lt;3% at the time of
             randomization (ie. optimal steroid dose)

          -  On Inhaled corticosteroids (ICS) and Long acting beta agonist (LABA) (irrespective of
             dose)

          -  Total serum IgE &gt;120 IU/L

          -  Age between 18 and 75 years

        Exclusion Criteria:

          -  Current smoker or ex-smokers with greater than 20 pack years

          -  Co-morbid diseases which in the investigator's opinion would make the patient
             unsuitable to participate in the study

          -  Currently on Omalizumab or has previously been treated with Omalizumab

          -  Currently on other biologic therapies

          -  Pregnancy or lactation

          -  Post bronchodilator FEV1 less than 50% predicted
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Parameswaran Nair, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Louis-Philippe Boulet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Laval</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Catherine Lemiere, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Montréal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Martin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melanie Kjarsgaard</last_name>
    <phone>905-522-1155</phone>
    <phone_ext>33024</phone_ext>
    <email>mkjarsga@stjoes.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Parameswaran Nair, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Laval</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 29, 2014</lastchanged_date>
  <firstreceived_date>January 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>McMaster University</investigator_affiliation>
    <investigator_full_name>Parameswaran Nair</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Prednisone</keyword>
  <keyword>Eosinophils</keyword>
  <keyword>Immunoglobin E (IgE)</keyword>
  <keyword>Asthma</keyword>
  <keyword>Bronchitis</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Allergy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Omalizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
